Chilblain-like lesions (COVID-19 toes) have the same impact on family members than psoriasis systemically treated: insights from a case-control study targeting the pediatric population

G. Damiani, R. Finelli, K. Kridin, A. Pacifico, N.L. Bragazzi, P. Malagoli, G. Fabbrocini, E. Bonifazi, F. Mazzotta, C. Lovati, P. Savoia, L.C. Gironi, M. Morello, T. Davidson, A. Watad, F. Goker, C. Mortellaro, M. Del Fabbro

Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. dr.giovanni.damiani@gmail.com

---

• Regenerative Medicine

OBJECTIVE: COVID-19 toes represent the main dermatological COVID-19 cutaneous manifestation in pediatric patients. Its diagnosis exposes the whole family to social stigma and this aspect was not previously evaluated.

PATIENTS AND METHODS: This was a multicenter, case-control, observational study that compared the family impact of COVID-19 toes vs. psoriasis (PsO). We enrolled 46 pediatric patients (23 with psoriasis and 23 with COVID-19 toes, age and gender matched) and their parents/caregivers that had to fill the Dermatitis Family Impact (DFI) questionnaire.

RESULTS: DFI index did not differ significantly between both subgroups (p=0.48), and in psoriatic patients did not correlate with both Psoriasis Area Severity Index (PASI) (p=0.59) and itch-VAS (p=0.16).

CONCLUSIONS: COVID-19 toes, a transitory dermatosis, exerted a similar impact/perturbation on family dynamics than PsO, a well-known stigmatizing, chronic inflammatory dermatosis.

Free PDF Download